Novartis AG
Novartis AG is a multinational pharmaceutical company with a dominant political signal being $63.9M in 2024 doctor payments to its subsidiary Advanced Accelerator Applications, while showing zero federal contract, lobbying, or corporate insider activity.
BusinessWhat NVS does
Novartis AG operates as a global healthcare company, developing and commercializing prescription medicines, generics, and specialty therapies. Its revenue is derived from innovative pharmaceuticals, oncology drugs, biosimilars, and gene therapies. Key subsidiaries include Sandoz Inc., Novartis Pharmaceuticals Corporation, and Advanced Accelerator Applications.
12 months past · 3 months futureNVS activity timeline
Lifetime Government AwardsNVS federal contracts
NVS doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding NVS
Politicians Trading NVSMembers of Congress with recent NVS positions
Congressional TradesWho in Congress is trading NVS
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting NVSLive legislation impacting this stock
Political ProfileWhere NVS sits in Washington
[object Object]
STRUCTURAL: High regulatory density (score 85) from healthcare sector exposure and $63.9M in doctor payments (get_political_influence.doctor_payments). EVIDENTIARY: No federal contracts (get_government_precedent.federal_contracts_summary is null), zero lobbying spend, zero corporate insider buys in 180 days (get_corporate_insider_signal.total_buys: 0), and no executive branch holdings. Net: Significant structural regulatory interface but no evidentiary political engagement or trading signals.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
Heightened scrutiny of physician payments under transparency lawsCMS/Open Payments"get_political_influence.doctor_payments shows $63.9M in 2024 payments from Advanced Accelerator Applications."
Regulatory opportunities
-
Potential for favorable reimbursement policies for radiopharmaceuticals and gene therapiesCMS"High-value doctor payment program for Advanced Accelerator Applications ($63.9M) indicates commercial engagement in specialized therapeutic areas."
Live signals + predictions for NVS — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades NVS
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord